mammography News
-
Showcase
Mobile Mammography
bout two years after the outbreak of COVID-19, many resources are still being used in the fight against this new virus. Nevertheless, the number of breast cancer cases in Italy are still very high: according to the report “The numbers of cancer in Italy”, published by AIRTUM and AIOM, in 2020 about 55.000 new cases were diagnosed in Italy among women (as of today, estimates for 2021 ...
-
Mammograms and Disabilities
People with disabilities (be they motor, sensory, or cognitive) now represent about 15% of the planet’s population (approximately 1 in 7 people). These are men and women who have the same need for health prevention screenings as people who do not have limitations. Despite current improvements (just think of the overcoming of architectural barriers in most buildings), it is quite evident ...
-
FDA 510 (k) clearance for Helianthus Digital Mammography System
We are happy to announce that on December 15, 2021, Metaltronica SpA has received 510(k) clearance from the U.S. Food and Drug Administration for its Helianthus Full-Field Digital Mammography ...
-
InHealth (North and East Devon NHS Breast Screening Unit) signing up to the AI in Health & Care Award with Kheiron Medical Technologies
InHealth, who provide services for North and East Devon NHS Breast Screening, has entered into the research agreement to work with Kheiron Medical Technologies as part of the AI in Health & Care Award. This partnership marks another significant step in the journey to build an evidence base to demonstrate the effectiveness and safety of artificial intelligence in NHS breast cancer screening. ...
-
Showcase
Northern Arizona, Verde Valley MC Highlights VeraForm; Importance Marking Breast Surgical Site
As a patient facing breast cancer surgery, you should know that precise "marking" of your cancer surgical site is an important part of your treatment. A marker is a device inserted at the surgical site. Precision in marking helps make sure you retain as much normal breast tissue as possible with the surgery. This ultimately leads to best overall post-surgical care by your wellness team. A new ...
-
QView Medical in Support of Breast Cancer Awareness Month Joins the Initiative of AmIDense.com
QView Medical is the only FDA AI Ultrasound Technology approved for breast screening. But now, we are moving beyond the clinical suite. QView is joining women in the initiative around Breast Cancer with the launch of AmIDense.com and the supporting #AmIDense. Let's START the conversation around Breast Density. The 2021 American Cancer Society's estimate is 280,000 women will be diagnosed with ...
-
Rezolut and CureMetrix Embark on AI Innovation Partnership
Rezolut, LLC and CureMetrix, Inc. have launched a pilot program in the Greater New York City area with the aim of pairing advanced technology with operational excellence to improve breast cancer detection in women receiving routine screening mammograms. Rezolut, LLC is a national, emerging platform of diagnostic medical imaging services, serving patients across the United States with 23 ...
-
Ultravist by Bayer now approved for contrast-enhanced mammography in EU
Ultravist-300, -370 receives green light for indication extension for use in contrast-enhanced mammography (CEM) in a European Workshare Procedure CEM is emerging modality combining digital mammography with the administration of a contrast agent Strategically expands Bayer’s portfolio in breast imaging, including contrast agents and injectors Bayer announced today that its ...
By Bayer AG
-
Aidoc And Screenpoint Medical Announce Partnership To Provide Complete Ai Solution For Breast Imaging
Aidoc’s comprehensive AI continues to expand to cover the majority of radiology adult subspecialties Aidoc, the leading provider of AI for medical imaging, and ScreenPoint Medical, leader of deep learning AI for 2D and 3D mammography, today announced a collaboration which will incorporate ScreenPoint’s capabilities into Aidoc’s platform. Breast imaging specialists will now be ...
By Aidoc
-
New Research Shows CureMetrix AI More Accurately Flags Anomalies in Mammograms and Improves Turnaround Time
New research finds that artificial intelligence (AI) by CureMetrix, Inc., a global healthcare technology company that develops AI-driven software for radiology, can greatly improve turnaround time for mammogram results and more accurately flag anomalies in a mammogram. The Journal of the American College of Radiology (JACR) has published a case study documenting the two-year, in-practice clinical ...
-
AMA recognizes Dedicated Breast CT by assigning 6 CPT Codes
On June 15th, 2020, the American Medical Association (AMA) granted 6 Category III CPT codes for the FDA PMA cleared dedicated breast CT imaging procedure. The newly assigned CPT codes in addition to the previous FDA PMA clearance process, formally introduces access to this new and advanced modality on January 1, 2021. The AMA technical subcommittee, comprised of prominent members of the ...
-
New Insights on AI for Radiology being delivered by CureMetrix at RSNA 2021 Annual Meeting
CureMetrix, Inc., a global healthcare technology company that develops AI-based software for radiology, will present multiple in-person and virtual sessions at the 2021 Radiological Society of North American (RSNA) Scientific Assembly and Annual Meeting, a hybrid event that will take place both online and live at McCormick Place in Chicago, IL, November 28 to December 2, 2021. Notably, at the ...
-
Transpara AI Breast Care - Global Expansion planned for 2022
Following the success of the world's leading AI Breast Care system, Transpara®, now in use across the US and in 30 countries worldwide, ScreenPoint Medical, the company that developed Transpara, is to launch a major expansion. The FDA and CE marked Transpara AI software reads mammograms to find cancers faster and at an earlier stage. 2022 will see a larger global team and further research ...
-
QView Medical Signs European Distribution Agreement to sell AI/QVCAD for Breast Cancer Detection
QView Medical and Traf Intercontinental announce a distribution agreement under which Traf International will sell QView Medical's QVCAD System to breast imaging clinics in Europe. QVCAD is the AI solution to assist the radiologist in detecting breast cancer in 3D Automated Breast Ultrasound images In this post-CoVid-19 environment, QView Medical searched for a more direct sales focus in ...
-
QView Medical maintains leadership position in AI-powered breast cancer screening technology through alliance with GE Healthcare
QView Medical, a breast cancer detection pioneer and maker of the FDA-approved artificial intelligence (AI) software system for breast cancer screening, and GE Healthcare today announced that QView's QVCAD software can be launched on GE Healthcare's Invenia™ ABUS 2.0 (Automated Breast Ultrasound), which has an open platform technology that allows the integration of third-party AI tools for ...
-
QView Medical Inc. Announces FDA PMA Approval for QVCAD for the GE Invenia 3D Automated Breast Ultrasound System (“ABUS”)
QView Medical is pleased to announce FDA approval for QVCAD to be used with the GE Invenia™ ABUS in breast screening for asymptomatic dense breasted women whose mammogram was negative. QVCAD is the next generation CAD system for automated breast ultrasound ("ABUS") based on deep learning algorithms. The QVCAD innovative C-Thru technology combined with ABUS has demonstrated a 33% improved ...
-
Seno Medical Launches CONFIDENCE Registry Study for Imagio® Breast Imaging System
Texas-based Seno Medical Instruments, Inc. (Seno) has launched its CONFIDENCE registry to evaluate the efficacy of imaging with opto-acoustic/ultrasound (OA/US) to diagnose breast abnormalities including cancer using its groundbreaking Imagio® Breast Imaging System. Approximately twelve sites will participate in the international registry, with a target of over 600 total patients ...
-
Scion Medical Technologies receives FDA 510 (k) clearance for the Cassi Beacon tissue marker
Newton, MA –Scion Medical Technologies, LLC announces the introduction of the Cassi™ Beacon™ tissue marker, the company’s newest addition to the Cassi™ breast biopsy product portfolio. The Cassi Beacon tissue marker is a single use marker which is placed into soft tissue during breast biopsy procedures to radiographically mark a surgical site for easy location ...
-
Transpara breast AI reduces false positives and radiologists` workload in largest Danish screening programme
The team running the country's largest breast screening programme have shown that using Transpara breast AI further confirmed the enormous contribution of this technology to breast cancer detection: not only to reduce the number of false positives but also to reduce radiologists' workload by over 60%. In Copenhagen, the biannual breast screening programme for women aged from 50 to 69, has been ...
-
Transpara breast AI; strong clinical evidence evolves into real life screening use
The Transpara AI breast care solution, now being used in over 30 countries worldwide to find breast cancers faster and earlier, has 'remarkable potential' to reduce Radiologists' workload, according to a leading research team in Spain. The team at the renowned University Hospital Reina Sofia in Cordoba, has launched a world first prospective 2D AND 3D study to see how they could help ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you